Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Joseph E. Gilliam, President and COO of Glaukos Corp (NYSE:GKOS), not too long ago executed a collection of transactions involving the corporate’s frequent inventory. The transactions come because the inventory trades close to its 52-week excessive of $151.92, having delivered a powerful 86% return year-to-date. On December 20, Gilliam bought a complete of three,328 shares, producing proceeds of $498,715. The gross sales had been carried out at costs starting from $149.54 to $150.35 per share.
Along with these gross sales, Gilliam additionally exercised inventory choices to amass 3,328 shares of Glaukos frequent inventory. These choices had been exercised at costs of $39.10 and $69.30 per share, for a complete transaction worth of $198,829. The $8.2 billion market cap firm maintains sturdy monetary well being with a present ratio of 5.54, indicating ample liquidity to satisfy short-term obligations.
The transactions had been made underneath a Rule 10b5-1 buying and selling plan, which permits insiders of publicly traded firms to arrange a predetermined plan to promote firm inventory, serving to to keep away from considerations about insider buying and selling. Following these transactions, Gilliam holds 102,169 shares of Glaukos inventory. In accordance with InvestingPro evaluation, analyst worth targets for Glaukos vary from $115 to $162, with 12 further key insights out there to subscribers by way of the excellent Professional Analysis Report.
In different current information, Glaukos Company has submitted a New Drug Software (NDA) to the FDA for Epioxa, a non-invasive remedy for keratoconus. This growth marks a big step for Glaukos in its efforts to supply a much less invasive remedy choice for sufferers with this progressive eye illness. The submission consists of constructive knowledge from two Part 3 pivotal trials. If accepted, Epioxa could be the primary FDA-sanctioned, non-invasive corneal cross-linking remedy that preserves the corneal epithelium.
In monetary information, Glaukos secured roughly $53.2 million from unwinding a portion of its capped name transactions, initially entered into in reference to the issuance of its 2.75% Convertible Senior Notes due in 2027. Moreover, the corporate’s iDose income doubled within the third quarter of 2024, reaching roughly $8 million, with protection anticipated to considerably enhance by 2025.
Analysts have supplied diverse outlooks for Glaukos. Citi upgraded Glaukos from Impartial to Purchase, anticipating a constructive inflection in gross sales of its iDose product in 2025. Mizuho (NYSE:MFG) Securities retained a Impartial ranking on Glaukos however elevated the worth goal in anticipation of a big 12 months forward for the corporate. These are current developments within the continued development and potential of Glaukos Company.
This text was generated with the help of AI and reviewed by an editor. For extra info see our T&C.
